Ison G, Beaver JA, McGuinn WD Jr, et al. FDA approval: uridine
triacetate for the treatment of patients following fluorouracil or
capecitabine overdose or exhibiting early-onset severe toxicities
following administration of these drugs. Clin Cancer Res.
2016;22(18):4545-4549.
Brutcher E, Christensen D, Smith MH, et al. 5-fluorouracil and
capecitabine: assessment and treatment of uncommon early-onset, severe
toxicities associated with administration. Clin J Oncol Nurs.
2018;22(6):627-634.
Rodriguez RU. Public teleconference regarding licensing and
collaborative research opportunities for: methods and compositions
relating to detecting dihydropyrimidine dehydrogenase (DPD).
Fed Regist. 2008;73(129):38233. Accessed May 11, 2026.
https://www.gpo.gov/fdsys/pkg/FR-2008-07-03/pdf/E8-15182.pdf
Amstutz U, Froehlich TK, Largiadèr CR. Dihydropyrimidine
dehydrogenase gene as a major predictor of severe 5-fluorouracil
toxicity. Pharmacogenomics J. 2011;12(9):1321-1336.
Garcia JJ, Beers A, Reid P, et al. Economic model of uridine triacetate
versus supportive care for the treatment of patients with
life‑threatening early‑onset severe toxicity.
Clin Drug Invest. 2025;45:111-123.
Santos C, Morgan BW, Gellar RJ. The successful treatment of
5-fluorouracil (5-FU) overdose in a patient with malignancy and
HIV/AIDS with uridine triacetate. Am J Emer Med.
2017;35(5):802.e7-802.e8.
Cordier PY, Nau A, Ciccolini J, et al. 5-FU–induced neurotoxicity in
cancer patients with profound DPD deficiency syndrome: a report of two
cases. Cancer Chemother Pharmacol. 2011;68(3):823-826.
Data on file. BTG International Inc. 2023.
Codacci-Pisanelli G, Noordhuis P, van der Wilt CL, Peters GJ.
Selective protection by uridine of growth inhibition by 5-fluorouracil
(5FU) mediated by 5FU incorporation into RNA, but not the thymidylate
synthase mediated growth inhibition by 5FU-leucovorin.
Nucleosides Nucleotide, Nucleic Acids. 2008;27(6):733-739.
Ma WW, Saif MW, El-Rayes BF, et al. Emergency use of uridine
triacetate for the prevention and treatment of life-threatening
5-fluorouracil and capecitabine toxicity. Cancer.
2017;123(2):345-356.
Garcia RAG, Saydoff JA, Bamat MK, von Borstel RW. Prompt treatment
with uridine triacetate improves survival and reduces toxicity due to
fluorouracil and capecitabine overdose or dihydropyrimidine
dehydrogenase deficiency. Toxicol Appl Pharmacol.
2018;353:67-73.
Ma WW, Saif MW, El-Rayes, BF et al (2017), Emergency Use of
Uridine Triacetate for the Prevention and Treatment of Life-Threatening
5-Fluorouracil and Capecitabine Toxicity. Cancer 123(2):345-356
Ison G et al. (2016), FDA approval: Uridine triacetate for the treatment
ofpatients following fluorouracil or capecitabine overdose or exhibiting
early-onset severe toxicides following administration of these drugs. Clin
Cancer Res 22(18): 1-5
Brutcher E et al. (2018) Assessment and Treatment of Uncommon, Early-
onset, Severe Toxicides Associated With 5-Fluorouracil and
Capecitabine. Clin J Oncology Nursing 22 (6): 627-634
Polk A. et al. (2016). Incidence and risk factors for capecitabine-induced
symptomatic cardiotoxicity: A retrospective study o f452 consecutive
patients with metastatic breast cancer. BMJ Open, 6, e012798
Genentech, Inc. (2016). Xeloda® (capecitabine) Package Insert
Meulendijks, D et al. (2016) Renal function, body surface area, and age
are associated with risk of early-onset fluoropyrimidine-associated
oxicity in patients treated with capecitabine-based anticancer regimens
in daily clinical care. European Journal of Cancer, 54, 120-130
Froehlich TK et al. (2015). Clinical importance of risk variants in the
dihydropyrimidine dehydrogenase gene for the prediction of early-onset
fluoropyrimidine toxicity. International Journal of Cancer, 136, 730-739
Mitani S et al. (2017) Acute hyperammonemic encephalopathy after
fluoropyrimidine-based chemotherapy: A case series and review of the
literature Medicine 96:22(e6874)
Etienne-Grimaldi M-C et al. (2017) New advances in DPYD genotype
and risk of severe toxicity under capecitabine. PLOS ONE, 12, e0175998
Hamzic S et al. (2018) Come a long way, still a ways to go: from
predicting and preventing fluoropyrimidine toxicity to increased
efficacy? Pharmacogenomics 19(8):689-692 Published Online: 22 May
2018
Rodriguez RU. Public teleconference regarding licensing and
collaborative research opportunities for: methods and compositions
relating to detecting dihydropyrimidine dehydrogenase (DPD). Fed
Regist. 2008; 73(129):38233
Andre T et al. (2004) Oxaliplatin, fluorouracil, and leucovorin as
adjuvant treatment for colon cancer N Engl J Med. 2004;350: 2343-2351
Sara JD et al. (2018) 5-fluorouracil and cardiotoxicity: a review
Therapeutic Advances in Medical Oncology Vol 10: 1-18
Peng J et al. (2018) Cardiotoxicity of 5-fluorouracil and capecitabine in
Chinese patients: a prospective study Cancer Communications; 38(22):
1-7
Yeh KH and Cheng AL (1997) High-dose 5-fluorouracil infusional
herapy is associated with hyperammonaemia, lactic acidosis and
encephalopathy Brit. J Cancer 75(3): 464-465
Cordier P-Y et al. (2011). 5-FU-induced neurotoxicity in cancer patients
with profound DPD deficiency syndrome: A report of two cases. Cancer
Chemotherapy and Pharmacology, 68, 823-826
BTG International Inc. (2023) Vistogard (uridine triacetate) Oral Granules Package Insert
Garcia R et al. (2018) Prompt treatment with uridine triacetate improves
survival and reduces toxicity due to fluorouracil and capecitabine
overdose or dihydropyrimidine dehydrogenase deficiency Toxicology
and Applied Pharmacology 353 (2018) 67-73
Baldeo C et al. (2018) Uridine triacetate for severe 5-fluorouracil
toxicity in a patient with thymidylate synthase gene variation: Potential
pharmacogenomic implications (Case Report). SAGE Open Medical
Case Reports Volume 6: 1-4
Vaudo CE et al. (2016) Early-Onset 5-Fluorouracil Toxicity in a Patient
Negative for Dihydropyrimidine Dehydrogenase Mutations: The Clinical
Course of Reversal with Uridine Triacetate. Pharmacotherapy 36(11)
e178-e182
Santos C et al. (2017) The successful treatment of 5-fluorouracil (5-FU)
overdose in a patient with malignancy and HIV/AIDS with uridine
triacetate. American Journal of Emergency Medicine 35(5) 802.e7-
802.e8
Chu E (2014) Epidemiology and natural history of central venous access
device use and infusion pump function in the NO16966 trial Brit J Cancer
110, 1438-1445 doi: 10.1038/bjc
You are now leaving the patient site.
The section you selected contains information intended for U.S. healthcare professionals only.
Please certify that you are a U.S. healthcare professional by clicking the link below.
